Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Fortrea Holdings Inc. (FTRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: FTRE (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
12 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $7.44
1 Year Target Price $7.44
| 0 | Strong Buy |
| 1 | Buy |
| 10 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 3.11% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 876.22M USD | Price to earnings Ratio - | 1Y Target Price 7.44 |
Price to earnings Ratio - | 1Y Target Price 7.44 | ||
Volume (30-day avg) 12 | Beta 1.8 | 52 Weeks Range 3.97 - 25.28 | Updated Date 08/29/2025 |
52 Weeks Range 3.97 - 25.28 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-06 | When - | Estimate 0.08 | Actual 0.19 |
Profitability
Profit Margin -37.57% | Operating Margin (TTM) -1.54% |
Management Effectiveness
Return on Assets (TTM) -1.42% | Return on Equity (TTM) -100.49% |
Valuation
Trailing PE - | Forward PE 12.53 | Enterprise Value 2036020000 | Price to Sales(TTM) 0.32 |
Enterprise Value 2036020000 | Price to Sales(TTM) 0.32 | ||
Enterprise Value to Revenue 0.74 | Enterprise Value to EBITDA 92.35 | Shares Outstanding 90800000 | Shares Floating 83919176 |
Shares Outstanding 90800000 | Shares Floating 83919176 | ||
Percent Insiders 0.48 | Percent Institutions 111.3 |
Upturn AI SWOT
Fortrea Holdings Inc.
Company Overview
History and Background
Fortrea Holdings Inc. was formed in 2023 as a spin-off from Laboratory Corporation of America Holdings (Labcorp). It focuses on providing clinical development and commercialization solutions to the pharmaceutical and biotechnology industries.
Core Business Areas
- Clinical Development: Offers a comprehensive suite of clinical development services, including early development, Phase I-IV clinical trials, and post-market studies.
- Commercialization: Provides commercialization services such as market access consulting, medical affairs, and patient support programs.
Leadership and Structure
Fortrea is led by a team of experienced executives in the clinical research and pharmaceutical industries. Its organizational structure is designed to support its global operations and client-centric approach.
Top Products and Market Share
Key Offerings
- Clinical Trial Management: Manages clinical trials for pharmaceutical and biotech companies, including protocol development, site selection, patient recruitment, data management, and statistical analysis. Competitors include IQVIA, PPD (Thermo Fisher Scientific), and ICON. Market share data is difficult to obtain precisely due to the fragmented nature of the clinical trial management market.
- Post-Approval Services: Provides post-approval services such as market access consulting, medical affairs, and patient support programs. Competitors include Syneos Health and Parexel. Market share data is difficult to obtain precisely due to the fragmented nature of the market.
Market Dynamics
Industry Overview
The clinical research organization (CRO) industry is experiencing growth driven by increasing R&D spending in the pharmaceutical and biotechnology sectors, the rising complexity of clinical trials, and the globalization of clinical research.
Positioning
Fortrea is positioned as a full-service CRO offering a broad range of services from early-stage development to commercialization. Its competitive advantage lies in its experienced team, global reach, and technology-enabled solutions.
Total Addressable Market (TAM)
The global CRO market is projected to reach hundreds of billions of dollars. Fortrea is positioned to capture a significant share of this market through its comprehensive service offerings and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Comprehensive service offerings
- Experienced management team
- Global reach
- Technology-enabled solutions
- Strong relationships with pharmaceutical and biotechnology companies
Weaknesses
- Relatively new company (spin-off)
- Integration challenges following the spin-off
- Dependence on the pharmaceutical and biotechnology industries
- Exposure to regulatory changes
Opportunities
- Expanding into new geographic markets
- Developing innovative technology solutions
- Acquiring smaller CROs to expand service offerings
- Growing demand for clinical trial services in emerging markets
Threats
- Increased competition from other CROs
- Economic downturn impacting pharmaceutical and biotechnology R&D spending
- Changes in regulatory requirements
- Loss of key personnel
Competitors and Market Share
Key Competitors
- IQVIA (IQV)
- Thermo Fisher Scientific (TMO)
- Syneos Health (SYNH)
Competitive Landscape
Fortrea faces intense competition from larger, more established CROs. Its success will depend on its ability to differentiate itself through innovation, service quality, and customer relationships.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's recent spin-off.
Future Projections: Future growth is projected to be driven by the growth in the CRO market and Fortrea's ability to capture market share.
Recent Initiatives: Recent initiatives may include strategic partnerships, acquisitions, and the launch of new service offerings.
Summary
Fortrea is a relatively new company with potential in the growing CRO market. Its comprehensive service offerings and experienced team are strengths, but it faces competition from larger players. Its success will depend on its ability to innovate and capture market share while effectively managing its integration as a spin-off.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Analyst estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data are estimates and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fortrea Holdings Inc.
Exchange NASDAQ | Headquaters Durham, NC, United States | ||
IPO Launch date 2023-07-03 | CEO & Director Mr. Anshul Thakral | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14500 | Website https://www.fortrea.com |
Full time employees 14500 | Website https://www.fortrea.com | ||
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical services that provides development and consulting services to clinical pharmacology and clinical development spectrum. The company also offers delivery models that include full service, functional service provider, and hybrid service structures. In addition, it delivers phase I " IV clinical trial management, clinical pharmacology, and consulting services. Fortrea Holdings Inc. enters into a strategic collaboration with Emery Pharma to provide rapid lot-by-lot, 1-methyl-4-nitrosopiperazine (MNP) testing of rifampin, the preferred drug for drug-drug interaction studies, to certify impurities are below the Acceptable Intake Limit set by U.S. Food and Drug Administration guidelines. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.